Case-Control Study of Simian Virus 40 and Non-Hodgkin Lymphoma in the United States
Open Access
- 14 September 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 96 (18) , 1368-1374
- https://doi.org/10.1093/jnci/djh266
Abstract
Background: Recent studies have reported detection of simian virus 40 (SV40) DNA in tumor tissues from 15%–43% of U.S. non-Hodgkin lymphoma (NHL) patients. SV40 accidentally contaminated U.S. poliovirus vaccines that were widely administered from 1955 through 1962. However, epidemiologic data linking SV40 with NHL are lacking. Methods: We obtained serum samples from 724 incident NHL case patients and 622 control subjects from a population-based U.S. case–control study. SV40 serostatus was analyzed by two independent laboratories (designated A and B) using similar virus-like particle (VLP) enzyme immunoassays. Associations with serostatus were assessed with logistic regression, adjusting for sex, race, birth year, and study site. VLPs for the human polyomaviruses BK and JC were used in competitive inhibition experiments to assess the specificity of SV40 reactivity. Statistical tests were two-sided. Results: SV40 antibody results from the two laboratories were correlated ( R = 0.59; P <.001). Laboratories A and B detected SV40 seropositivity in 7.2% and 9.8% of NHL case patients, respectively, and in 10.5% and 9.6% of control subjects, respectively. SV40 seropositivity was not associated with increased NHL risk (laboratory A: adjusted odds ratio [OR] = 0.68, 95% confidence interval [CI] = 0.46 to 1.00; laboratory B: adjusted OR = 1.02, 95% CI = 0.71 to 1.47). SV40 seropositivity was not associated with NHLs of any specific histology or site. Among subjects born before 1963, 1.0%–1.6% showed SV40-specific reactivity, i.e., SV40 reactivity confirmed in competitive inhibition experiments, whereas (based on limited data) none born subsequently demonstrated SV40-specific reactivity. Conclusions: In persons born before 1963, the presence of SV40-specific antibodies, although rare, could reflect exposure to SV40-contaminated vaccines. Nevertheless, NHL risk was unrelated to serologic evidence of SV40 exposure or infection.Keywords
This publication has 23 references indexed in Scilit:
- Hepatitis C virus infection and non‐hodgkin lymphoma: Results of the NCI‐seer multi‐center case‐control studyInternational Journal of Cancer, 2004
- Inability of Simian Virus 40 To Establish Productive Infection of Lymphoblastic Cell LinesJournal of Virology, 2004
- Childhood exposure to simian virus 40‐contaminated poliovirus vaccine and risk of AIDS‐associated non‐Hodgkin's lymphomaInternational Journal of Cancer, 2003
- Lack of serological evidence for an association between simian virus 40 and lymphomaInternational Journal of Cancer, 2003
- Simian virus 40 infectionin lymphoproliferative disordersThe Lancet, 2003
- Association between simian virus 40 and non-Hodgkin lymphomaThe Lancet, 2002
- Presence of simian virus 40 DNA sequences in human lymphomasThe Lancet, 2002
- Thirty-five year mortality following receipt of SV40- contaminated polio vaccine during the neonatal periodBritish Journal of Cancer, 2001
- HUMAN EXPOSURE TO SV40: REVIEW AND COMMENT12American Journal of Epidemiology, 1976
- Leukemia, Lymphoma, and Osteosarcoma Induced in the Syrian Golden Hamster by Simian Virus 40Science, 1972